Aligos Therapeutics, Inc.【ALGS】

時価総額

$617.6万

PER

小分子とオリゴの創薬を行うバイオ医薬の新興企業。ALG‑125755の第1相（20–200mg/50–320mg）でHBsAg低下を確認したHBV治療候補を展開。Merckとの共同研究に加え2023年5月にAmoytopから700万ドルの前受金を受領。米国・欧州を中心に展開。

株価業績

サマリーテーブルに戻る

	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-109	-128	-96	-88	-131
Accretion of discount on investments	-0	-0	0	0	2
Amortization of right of use assets	1	1	1	2	2
Operating Lease, Impairment Loss	-	-	-	1	-
Fair Value Adjustment of Warrants	1	-	-	2	46
Loss on disposal of assets	-	-	-	-0	-
Depreciation	3	3	2	2	1
Stock-based compensation including ESPP	3	13	15	13	8
Other assets	4	8	-6	-2	-0
Right of use assets	-	-	0	-	-
Accounts payable	-0	-0	2	-2	0
Accrued liabilities	10	10	-9	1	-1
Operating lease liabilities	-1	-1	-2	-2	-3
Other liabilities	-	-0	-0	0	-
Deferred revenue	-	-	3	-9	-1
Net cash and cash equivalents used in operating activities	-74	-116	-79	-79	-81
Maturities of short-term investments	80	23	79	45	90
Purchase of short-term investments	32	3	104	0	108
Purchases of long-term investments	13	16	-	-	-
Purchases of property and equipment	2	1	1	0	0
Net cash and cash equivalents (used in) provided by investing activities	33	3	-26	45	-18
Proceeds From Issuance Of Common Stock In Connection With PIPE Offering Net Of Costs	-	-	-	17	-
Proceeds From Issuance Of Pre Funded Warrants In Connection With PIPE Offering Net Of Costs	-	-	-	45	-
Proceeds From Issuance Of Common Warrants In Connection With PIPE Offering Net Of Costs	-	-	-	25	-
Proceeds from issuance of common stock upon exercise of pre funded warrants	-	-	-	-	0
Payments on finance lease	0	0	0	0	0
Proceeds from Stock Plans	-	-	0	1	0
Follow-on Offering	-	79	-	-	-
Employee Stock	-	1	0	0	-
Net cash and cash equivalents provided by financing activities	192	79	0	88	0
Net (decrease)/increase in cash, cash equivalents, and restricted cash	151	-34	-106	54	-99
Mark to market adjustment for available-for-sale investments	0	-0	-0	0	0
Receviable due from arrangement	-	-	1	-	-
Equipment acquired through finance lease	-	0	-	-	-
Acquisition of right of use asset through operating lease obligation	-	3	-	1	-
Vesting of early exercised options	0	0	0	0	-
PP&E Purchase still in Accounts Payable	0	0	-	-	-
Change in pension obligation	-0	1	0	0	-0
Net exercise of common warrants	-	-	-	-	1